Findings from a literature review indicate that overall costs of long-acting insulin analogues are not significantly different from those of intermediate-acting human insulin and oral antidiabetic agents.
Lisa Bloudek, PharmD, MS
Advertisement
Articles by Lisa Bloudek, PharmD, MS
Advertisement
Latest Updated Articles
- Costs Associated With Long-Acting Insulin Analogues in Patients With Diabetes
Published: July 11th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Value-Based Care Interventions and Management of CKD Progression
4
Defining the Role of Rilzabrutinib in ITP Management
5
